| Literature DB >> 32920244 |
Vincenzo Carrieri1, Leonardo Madio2, Francesco Principe3.
Abstract
Governments worldwide are increasingly concerned about the booming use of CBD (cannabidiol) products. However, we know little about the impact of their liberalization. We study a unique case of unintended liberalization of a CBD-based product (light cannabis) that occurred in Italy in 2017. Using unique and high-frequency data on prescription drug sales and by exploiting the staggered local availability of the new product in each Italian province, we document a significant substitution effect between light cannabis and anxiolytics, sedatives, opioids, anti-depressants and anti-psychotics. Results are informative for regulators and suggest that bans on light cannabis use would disregard the needs of patients to seek effective reliefs of their symptoms.Entities:
Keywords: CBD; Difference-In-Difference; Light cannabis; Marijuana; Prescription drugs; Self-Medication
Year: 2020 PMID: 32920244 DOI: 10.1016/j.jhealeco.2020.102371
Source DB: PubMed Journal: J Health Econ ISSN: 0167-6296 Impact factor: 3.883